摘要
目的探讨恩替卡韦联合胸腺肽α1治疗乙型病毒性肝炎肝硬化伴糖尿病的疗效与预后。方法选取2016年1月至2017年12月大同市第四人民医院住院治疗的160例乙型病毒性肝炎肝硬化伴糖尿病患者,随机分为对照组和试验组,每组80例。对照组给予恩替卡韦治疗和临床常规护肝治疗,试验组在对照组的基础上予以胸腺肽α1联合治疗。比较两组患者治疗前后症状体征和生化指标的差异,计算不良药物反应发生率,分析两组患者治疗预后。结果治疗后,两组患者症状体征、肝功能指标、肝纤维化指标、糖代谢指标均改善(P<0.05);试验组症状体征、肝功能指标、肝纤维化指标、糖代谢指标与对照组比较,差异有统计学意义(P<0.05)。试验组乏力、厌食、腹胀改善率更高,肝功能指标恢复更好,肝纤维化程度下降,糖代谢水平恢复更好。试验组不良药物反应发生率为5.0%,低于对照组(15.0%,P<0.05)。试验组HBV-DNA转阴率和HBeAg转阴率均高于对照组(P均<0.05)。结论恩替卡韦联合胸腺肽α1治疗乙型病毒性肝炎肝硬化伴糖尿病疗效较单一用药好,安全性更高,能够减少疾病不良预后的发生,具有临床推广价值。
Objective To investigate the efficacy and prognosis of entecavir combined with thymosin α1 on hepatitis B cirrhosis patients with hepatogenous diabetes. Methods A total of 160 cases of hepatitis B cirrhosis with diabetes in the Fourth People’s Hospital of Datong from January 2016 to December 2017 were selected as the research subjects, and they were randomly divided into the control group and the experimental group, with 80 cases in each group. The control group was given entecavir treatment and clinical routine liver protection treatment. The experimental group was treated with thymosin α 1 on the basis of the treatment in the control group. The differences of symptoms and signs and biochemical indexes before and after treatment in the two groups were compared. The the incidences of adverse drug reactions were calculated, and the prognosis of the two groups was analyzed. Results After treatment, the symptoms and signs, liver function indexes, liver fibrosis indexes and glycometabolism indexes were improved in the two groups (P<0.05);there were significant differences in the symptoms and signs, liver function indexes, liver fibrosis indexes and glucose metabolism indexes between the two groups (P<0.05). In the experimental group, the improvement rates of asthenia, anorexia, abdominal distention were higher, liver function indexes recovered better, liver fibrosis degree decreased, and glucose metabolism levels recovered better. The incidence of adverse drug reaction in the experimental group was 5%, which was lower than that in the control group (15%, P<0.05). The negative rate of HBV-DNA and the negative rate of HBeAg in the experimental group were higher than those in the control group (P<0.05). Conclusions The effect of entecavir and thymosin α 1 on hepatitis B cirrhosis with diabetes is better than single drug, which has higher safety, and can reduce the incidence of ill prognosis.
作者
张海霞
Zhang Haixia(Department of Severe Hepatology, the Fourth People’s Hospital of Datong, Datong 037008, China)
出处
《中国实用医刊》
2019年第6期88-92,共5页
Chinese Journal of Practical Medicine
